Skip to content
MARKETS / NASDAQ / SPRC
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

SciSparc Ltd. SPRC

10 fiscal years on record · USD · FY2024 reported · SEC filings only
$1.3M
▼ 54.6% YoY
$-6.3M
In brief

What this company does

We, through our subsidiary NeuroThera, engage in clinical-stage pharmaceutical developments. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. We also have a majority-owned subsidiary, held by NeuroThera, whose business focuses on the sale of hemp seed oil-based products and others on Amazon Marketplace. SCI-110 is a proprietary drug candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and (2) CannAmide™, a proprietary PEA, formulation.

Written from the business description in SciSparc Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 29 April 2026. Every sentence was checked against that document before publication.

Growth
USD 1.3M
Revenue, FY2024 · full 10-year series below
Revenue $M Net income $M
FY2024 · Revenue 1.3 · Net income -6.3
1.0M2.0M-2.5M-5.0M2015201620172018201920202021202220232024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−572 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -560.2% · Net -572.1%
-200%-400%-600%2015201620172018201920202021202220232024
ROE
FY2024 · ROE -79.7%
10000%20000%2015201620172018201920202021202220232024

Each USD of equity lost 80 cents this year.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -12.8
-5M-10M2015201620172018201920202021202220232024

Total assetsUSD 10.3M
EquityUSD 8.2M
CashUSD 1.5M
Current ratio5.36×

Equity funds 79% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320222021202020192018201720162015
Revenue $B0.00.00.0·······
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
EBITDA $B··········
Income tax $B−0.00.00.0···−0.0···
Net income $B−0.0−0.0−0.0−0.00.00.00.00.00.00.0
Free cash flow $B··−0.0−0.0·−0.0−0.0−0.0−0.0−0.0
EPS, diluted $1.2814.43−14.82−73.580.110.601.20···
Dividend / sh $··········
Payout %··········
ROE %−79.7−72.8−40.2·25250.04709.5198.874.4··
Shares out B0.010.000.000.000.000.010.140.140.04·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 2 failures in 35 reconciliationsAUDITED

Reconciled in 8 of 19 fiscal years. 60 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image